Search
Research
FeBRILe3– Fever, Blood cultures and Readiness for discharge in Infants Less than 3 months’ oldTom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,
Research
The NICE GUT TrialTom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,
Research
Transiently increased IgE responses in infants and pre-schoolers receiving only (DTaP) vaccines compared to those initially receiving at least one dose of DTwP vaccineConfirm the generalised IgE-trophic activity of the DTaP vaccine in pre-schoolers and demonstrate similar (albeit transient) effects in infants
Research
Respiratory syncytial virus is present in the neonatal intensive care unitThe results suggest that though the risk for RSV in the NICU remains low, personnel clothing are contaminated with RSV-RNA and may have a role in transmission
Research
Nitazoxanide for the treatment of infectious diarrhoea in the Northern Territory, Australia 2007-2012This paper examines the use of a new antibiotic to treat diarrhoea cause by Cryptosporidium infection in Australian Indigenous children.
Research
Management of invasive group A streptococcal infectionsInvasive group A streptococcal disease in children includes deep soft tissue infection, bacteraemia, bacteraemic pneumonia, meningitis and osteomyelitis
Research
Factors associated with adherence to antimicrobial stewardship after-hoursRestricted antimicrobials acquired after-hours are not routinely antimicrobial stewardship adherent at the time of acquisition or the next standard working day
Research
Topical versus systemic antibiotics for chronic suppurative otitis mediaTo assess the relative effectiveness of topical versus systemic antibiotics for people with chronic suppurative otitis media
Research
Advances in Vaccines to Prevent Viral Respiratory Illnesses in ChildrenChildhood vaccination has played a critical role in the reduction of morbidity and mortality from communicable diseases, including specific respiratory pathogens
Research
Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series AnalysisPalivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort